Remove Biosimilars Remove Disease Remove Therapies
article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

Targeting GPCRs to fight inflammatory diseases GPCR-targeting drugs are well known therapies for a range of disease types, including cardio-metabolic, central nervous system and endocrinological disorders.

Disease 59
article thumbnail

Bio-Techne Joins Forces with USP to Speed Up Development of mAbs and Gene Therapies

The Pharma Data

This alliance aims to address mounting challenges in the development and commercialization of mAb therapies and gene therapies, particularly those involving AAV vectors. Biologic drugs, including monoclonal antibodies, have become essential in the treatment of a wide array of conditions, from autoimmune diseases to various cancers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 billion by 2025, growing at a CAGR of 34.2%

article thumbnail

The MAHA Assessment’s Implications: Drugs (Part One)

FDA Law Blog: Biosimilars

The Strategy must address appropriately restructuring the Federal Governments response to the childhood chronic disease crisis, including by ending Federal practices that exacerbate the health crisis or unsuccessfully attempt to address it, and by adding powerful new solutions that will end childhood chronic disease.

Drugs 59
article thumbnail

Building the requisite clinical development infrastructure for medical innovation to thrive

Drug Target Review

They wait for the therapies that could significantly improve their quality of life or even save it knowing approval could be years or decades away. We are at a pivotal moment where we must consider how to improve these systems and ways of working to ensure critical therapies reach those who need them most.

article thumbnail

Salt Lake City

Alta Sciences

Stay connected linkedin youtube Footer Solutions Preclinical Services Clinical Services Manufacturing and Analytical Services Bioanalytical Services Research Support Services Development Programs News & Events Altasciences Events Press Releases Altasciences in the News Press Kit Resource Center The Altascientist Webinars/Podcasts Newsletters Scientific (..)

article thumbnail

Gretchen Green

Alta Sciences

Stay connected linkedin youtube Footer Solutions Preclinical Services Clinical Services Manufacturing and Analytical Services Bioanalytical Services Research Support Services Development Programs News & Events Altasciences Events Press Releases Altasciences in the News Press Kit Resource Center The Altascientist Webinars/Podcasts Newsletters Scientific (..)